- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02246465
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
February 21, 2018 updated by: RXi Pharmaceuticals, Corp.
An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Pedro Sula, Honduras, 21104
-
-
-
-
California
-
Beverly Hills, California, United States, 90210
-
-
Florida
-
Lake Worth, Florida, United States, 33461
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28028
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults, 21-55 years of age
- General good health
- Previous surgery or injury resulting in a hypertrophic scar
Exclusion Criteria:
- Scars on the face or front of neck may not be included in the trial
- Use of tobacco or nicotine-containing products
- Pregnant or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RXI-109
RXI-109 dosed at the site of the revised hypertrophic scar
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reducing the recurrence of hypertrophic scar after scar revision surgery
Time Frame: 9 months
|
To evaluate the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective scar revision surgery by review of photographic results and Patient and Observer Scar Assessment Scales.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety evaluation of RXI-109
Time Frame: 9 months
|
To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective revision of a hypertrophic scar
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (Actual)
December 1, 2017
Study Completion (Anticipated)
March 1, 2018
Study Registration Dates
First Submitted
September 16, 2014
First Submitted That Met QC Criteria
September 18, 2014
First Posted (Estimate)
September 22, 2014
Study Record Updates
Last Update Posted (Actual)
February 23, 2018
Last Update Submitted That Met QC Criteria
February 21, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RXI-109-1402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Scar
-
Iran University of Medical SciencesRecruitingDry Needling | Scar Tissue | Hypertrophic Scar | Hypertrophic Surgical Scar | Hypertrophic Scar of Upper Arm (Disorder)United States, Iran, Islamic Republic of
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
-
Universiti Kebangsaan Malaysia Medical CentreCompletedKeloid Scar Following Surgery | Caesarean Wound | Hypertrophic Surgical ScarMalaysia
-
Medstar Health Research InstituteCompletedBurn Scar | Hyperpigmentation | Hypertrophic Scar | Hypopigmented ScarUnited States
-
PfizerTerminatedHypertrophic Scars Resulting From Prior Breast Scar Revision SurgeryUnited States
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
Seoul National University HospitalCompletedHypertrophic Surgical ScarKorea, Republic of
-
Kaohsiung Medical UniversityUnknown
Clinical Trials on RXI-109
-
RXi Pharmaceuticals, Corp.UnknownAge-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal FibrosisUnited States
-
RXi Pharmaceuticals, Corp.Completed
-
RXi Pharmaceuticals, Corp.CompletedHypertrophic ScarUnited States, Honduras
-
RXi Pharmaceuticals, Corp.CompletedKeloidUnited States, Dominican Republic
-
RXi Pharmaceuticals, Corp.CompletedCicatrix | Scar PreventionUnited States
-
Coronado Biosciences, Inc.Unknown
-
Hunan Province Tumor HospitalCompleted
-
Taiho Pharmaceutical Co., Ltd.TerminatedAdvanced Colorectal CancerUnited States
-
Lytix Biopharma ASCompletedAtopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/DermatosesHungary
-
Seres Therapeutics, Inc.CompletedClostridioides Difficile InfectionUnited States, Canada